Select Publications
Journal articles
2025, 'Unsuccessful Direct Acting Antiviral Hepatitis C Treatment Among People With HIV: Findings From an International Cohort', Liver International, 45, pp. 1 - 13, http://dx.doi.org/10.1111/liv.16203
,2024, 'Contribution of prison-based hepatitis C treatment initiations to overall treatment uptake in Victoria, Australia', The Lancet Regional Health - Western Pacific, 48, http://dx.doi.org/10.1016/j.lanwpc.2024.101139
,2024, 'Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data from a consortium of prospective cohort studies', The Lancet HIV, 11, pp. e106 - e116, http://dx.doi.org/10.1016/S2352-3018(23)00267-9
,2024, 'Cohort Profile: International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC)', International Journal of Epidemiology, 53, http://dx.doi.org/10.1093/ije/dyad154
,2024, 'Incidence of hepatitis C virus infection in the prison setting: The SToP-C study', Journal of Viral Hepatitis, 31, pp. 21 - 34, http://dx.doi.org/10.1111/jvh.13895
,2023, 'Reinfection incidence and risk among people treated for recent hepatitis C virus infection', AIDS, 37, pp. 1883 - 1890, http://dx.doi.org/10.1097/QAD.0000000000003651
,2023, 'Screening for Hepatitis C Virus Reinfection Using a Behaviour-Based Risk Score among Men Who Have Sex with Men with HIV: Results from a Case–Control Diagnostic Validation Study', Pathogens, 12, pp. 1248, http://dx.doi.org/10.3390/pathogens12101248
,2023, 'Sexual and drug use risk behaviour trajectories among people treated for recent HCV infection: the REACT study', Journal of the International AIDS Society, 26, pp. e26168, http://dx.doi.org/10.1002/jia2.26168
,2023, 'Hepatitis C Virus Reinfection in a Real-World Cohort of Homeless-Experienced Individuals in Boston', Clinical Infectious Diseases, 77, pp. 46 - 55, http://dx.doi.org/10.1093/cid/ciad127
,2023, 'Optimizing point-of-care testing strategies for diagnosis and treatment of hepatitis C virus infection in Australia: a model-based cost-effectiveness analysis', The Lancet Regional Health - Western Pacific, 36, http://dx.doi.org/10.1016/j.lanwpc.2023.100750
,2023, 'Corrigendum to ‘National trends in retreatment of HCV due to reinfection or treatment failure in Australia’ (J Hepatol [2023] 260–270) (Journal of Hepatology (2023) 78(2) (260–270), (S016882782203118X), (10.1016/j.jhep.2022.09.011))', Journal of Hepatology, 78, pp. 1084, http://dx.doi.org/10.1016/j.jhep.2023.02.020
,2023, 'Increasing national trend of direct-acting antiviral discontinuation among people treated for HCV 2016-2021', Hepatology Communications, 7, pp. e0125, http://dx.doi.org/10.1097/HC9.0000000000000125
,2023, 'National trends in retreatment of HCV due to reinfection or treatment failure in Australia', Journal of Hepatology, 78, pp. 260 - 270, http://dx.doi.org/10.1016/j.jhep.2022.09.011
,2023, 'Effectiveness of direct-acting antiviral therapy among Aboriginal and Torres Strait Islander peoples with HCV infection in Australia: A national real-world cohort (REACH-C)', Journal of Viral Hepatitis, 30, pp. 386 - 396, http://dx.doi.org/10.1111/jvh.13803
,2022, 'Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study', Clinical Infectious Diseases, 75, pp. 1809 - 1819, http://dx.doi.org/10.1093/cid/ciac246
,2022, 'Patterns and correlates of hepatitis C virus phylogenetic clustering among people living with HIV in Australia in the direct-acting antiviral era: A molecular epidemiology study among participants in the CEASE cohort', Health Science Reports, 5, http://dx.doi.org/10.1002/hsr2.719
,2022, 'Retreatment for hepatitis C virus direct-acting antiviral therapy virological failure in primary and tertiary settings: The REACH-C cohort', Journal of Viral Hepatitis, 29, pp. 661 - 676, http://dx.doi.org/10.1111/jvh.13705
,2022, 'High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH-C Study', Hepatology Communications, 6, pp. 496 - 512, http://dx.doi.org/10.1002/hep4.1826
,2021, 'Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort', International Journal of Drug Policy, 96, http://dx.doi.org/10.1016/j.drugpo.2021.103422
,2020, 'Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV', AIDS, 34, pp. 1347 - 1358, http://dx.doi.org/10.1097/QAD.0000000000002562
,Conference Papers
2021, 'Tolerability and antiviral activity of bictegravir/tenofovir alafenamide/emtricitabine (Biktarvy) treatment switch in patients aged 55 years or older with HIV: the BIO study', in HIV MEDICINE, WILEY, pp. 95 - 96, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000711388200103&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,Conference Abstracts
2022, 'Hepatitis C virus reinfection following direct acting antiviral treatment in the prison setting: the SToP-C study', in Journal of Hepatology, Elsevier BV, Vol. 77, pp. S565 - S565, http://dx.doi.org/10.1016/s0168-8278(22)01451-9
,Reports
2024, Monitoring hepatitis C treatment uptake in Australia: Issue #14, July 2024, Kirby Institute, UNSW, Sydney, 14, http://dx.doi.org/10.26190/unsworks/30340, https://www.kirby.unsw.edu.au/research/reports/monitoring-hepatitis-c-treatment-uptake-australia-issue-14-july-2024
,2023, Monitoring hepatitis C treatment uptake in Australia: Issue #13, July 2023, The Kirby Institute, UNSW, Sydney, Australia, http://dx.doi.org/10.26190/81wp-fr56, https://www.kirby.unsw.edu.au/research/reports/monitoring-hepatitis-c-treatment-uptake-australia-issue-13-july-2023
,Preprints
Optimizing Point-of-Care Testing Strategies for Diagnosis and Treatment of Hepatitis C Virus Infection in Australia: A Model-Based Cost-Effectiveness Analysis, http://dx.doi.org/10.2139/ssrn.4267510
,Optimizing Point-of-Care Testing Strategies for Diagnosis and Treatment of Hepatitis C Virus Infection in Australia: A Model-Based Cost-Effectiveness Analysis, http://dx.doi.org/10.2139/ssrn.4267527
,